Tumor Treating Fields (TTF) is a non-invasive physical therapy that uses low-intensity alternating electric fields at specific frequencies (100-300 kHz) to precisely disrupt key steps in cancer cell division (such as mitosis), thereby inhibiting tumor growth and inducing cancer cell death. This treatment requires no surgery or radiation, allowing patients to carry the portable device and maintain normal daily activities, achieving "treatment-life integration."

1. Non-Invasive and Pain-Free, Preserving Quality of Life

→ No surgery, radiation, or systemic chemotherapy toxicity;

→ Avoids surgical trauma and long-term side effects like tissue fibrosis or cognitive impairment caused by radiotherapy;

→ Patients maintain mobility during treatment, enabling work and social activities.

2. Precise Targeting of Cancer Cells While Protecting Healthy Tissue

→ Electric fields selectively disrupt rapidly dividing cancer cells, sparing normal resting cells;

→ Localized treatment prevents systemic immunosuppression, reducing infection risks.

3. Continuous Suppression of Recurrence, Extending Survival

→ Global clinical studies confirm: Significant extension of survival in recurrent glioblastoma patients (median survival increased by 40%+);

→ 24-hour wearable use suppresses micrometastases, lowering recurrence rates.

4. Convenient Home-Based Treatment, Reducing Healthcare Costs

→ Lightweight, portable device requires ≥18 hours of daily wear;

→ Minimizes frequent hospital visits, ideal for mobility-limited patients;

Currently primarily indicated for the following treatment-resistant tumors that have failed standard therapies:

Recurrent Glioblastoma (GBM):

→ Adult patients with recurrence after surgery, radiotherapy, and temozolomide chemotherapy (FDA/NMPA-approved indication)

Investigational Treatment for Advanced Solid Tumors (Under Clinical Research):

1.Patients with Recurrent High-Grade Glioma

→ Particularly glioblastoma (GBM) patients with recurrence after temozolomide chemotherapy

→ Those ineligible for repeat surgery or unable to tolerate re-irradiation

2.Patients Prioritizing Both Quality of Life and Long-Term Survival

→ Seeking to avoid sequelae from surgery/radiotherapy (e.g., neurological deficits)

→ Younger patients needing to maintain work or family responsibilities

3.Patients Exploring Combination Therapies for Advanced Cancer

→ Participating in international clinical trials (e.g., TTF combined with immunotherapy or targeted drugs) to pursue breakthrough treatment options